Trimerbody Pharma Overview
- Year Founded
-
2007
- Status
-
Private
- Employees
-
6
- Latest Deal Type
-
2ndary - Private
- Investors
-
2
Trimerbody Pharma General Information
Description
Developer of a proprietary immunotherapeutic platform designed to treat solid tumors. The company's technology utilizes a unique trimeric configuration of bispecific antibodies, providing tumor-specific immune activation and enhanced binding avidity to enable the development of next-generation therapeutic antibodies with improved safety profiles and anti-tumor activity.
Contact Information
Website
trimerbodypharma.comCorporate Office
- Calle de Santiago Grisolía 2
- Tres Cantos
- 28760 Madrid
- Spain
Corporate Office
- Calle de Santiago Grisolía 2
- Tres Cantos
- 28760 Madrid
- Spain
Trimerbody Pharma Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 4. Secondary Transaction - Private | Completed | Pre-Clinical Trials | ||||
| 3. Later Stage VC | 29-Apr-2021 | Completed | Startup | |||
| 2. Equity Crowdfunding | 28-Sep-2020 | $1.29M | $1.29M | Completed | Startup | |
| 1. Grant | 01-Jan-2017 | $472K | Completed | Startup |
Trimerbody Pharma Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Preference |
Trimerbody Pharma Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Trimerbody Pharma Patents
Trimerbody Pharma Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| JP-2024510947-A | Trimeric polypeptides and their use in cancer therapy | Pending | 05-Mar-2021 | ||
| EP-4301780-A1 | Trimeric polypeptides and uses thereof in the treatment of cancer | Pending | 05-Mar-2021 | ||
| US-20240092942-A1 | Trimeric polypeptides and uses thereof in the treatment of cancer | Pending | 05-Mar-2021 | ||
| WO-2022184937-A1 | Trimeric polypeptides and uses thereof in the treatment of cancer | Inactive | 05-Mar-2021 | ||
| JP-2021525537-A | Trimeric polypeptide complex and its use | Active | 06-Jun-2018 | C07K16/2878 |
Trimerbody Pharma Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Trimerbody Pharma Investors (2)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Bionexum Ventures | Venture Capital | Minority | ||
| Sociedad de Desarrollo de Navarra | Venture Capital | Minority |
Trimerbody Pharma FAQs
-
When was Trimerbody Pharma founded?
Trimerbody Pharma was founded in 2007.
-
Where is Trimerbody Pharma headquartered?
Trimerbody Pharma is headquartered in Madrid, Spain.
-
What is the size of Trimerbody Pharma?
Trimerbody Pharma has 6 total employees.
-
What industry is Trimerbody Pharma in?
Trimerbody Pharma’s primary industry is Drug Discovery.
-
Is Trimerbody Pharma a private or public company?
Trimerbody Pharma is a Private company.
-
What is Trimerbody Pharma’s current revenue?
The current revenue for Trimerbody Pharma is .
-
How much funding has Trimerbody Pharma raised over time?
Trimerbody Pharma has raised $3.19M.
-
Who are Trimerbody Pharma’s investors?
Bionexum Ventures and Sociedad de Desarrollo de Navarra have invested in Trimerbody Pharma.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
